Valsartan methyl ester
Based on 1 Customer Validation
Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.39%
- CAS. Nr.: 137863-17-3
- Formel: C25H31N5O3
- Molecular Weight:449.55
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult (12-week-old) male Wistar rats were administered Nω-nitro-L-arginine methyl ester (L-NAME) at a dose of 40 mg/kg/day dissolved in drinking water for 4 weeks to induce hypertension and hypertensive heart disease[1]
-
Dosage:68 mg/kg
-
Administration:p.o., daily, dissolved in drinking water, 4 weeks
-
Result:Achieved systolic blood pressure (SBP) reduction.
Showed no significant changes in body weight.
Reduced left ventricular weight (LVW).
Appeared increases in left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS).
Reduced hydroxyproline concentration in insoluble collagen and total collagen.
Reduced the volume of type I collagen and type III collagen.
Reduced serum prolactin level and serum prolactin receptor level.
Showed decreases in E/A ratio, deceleration time (DecT), and isovolumic relaxation time.
Chemical Information
-
CAS. Nr. 137863-17-3
-
Appearance Solid
-
Molecular Weight 449.55
-
Formel C25H31N5O3
-
Color White to off-white
-
SMILES
COC([C@H](C(C)C)N(C(CCCC)=O)CC1=CC=C(C=C1)C2=C(C3=NN=NN3)C=CC=C2)=O
-
Synonyms
CGP 48933 methyl ester
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 175 mg/mL (389.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Korean - KR (604 KB)
- Portuguese - PT (604 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2244 mL | 11.1222 mL | 22.2445 mL | 55.6112 mL |
| 5 mM | 0.4449 mL | 2.2244 mL | 4.4489 mL | 11.1222 mL | |
| 10 mM | 0.2224 mL | 1.1122 mL | 2.2244 mL | 5.5611 mL | |
| 15 mM | 0.1483 mL | 0.7415 mL | 1.4830 mL | 3.7074 mL | |
| 20 mM | 0.1112 mL | 0.5561 mL | 1.1122 mL | 2.7806 mL | |
| 25 mM | 0.0890 mL | 0.4449 mL | 0.8898 mL | 2.2244 mL | |
| 30 mM | 0.0741 mL | 0.3707 mL | 0.7415 mL | 1.8537 mL | |
| 40 mM | 0.0556 mL | 0.2781 mL | 0.5561 mL | 1.3903 mL | |
| 50 mM | 0.0445 mL | 0.2224 mL | 0.4449 mL | 1.1122 mL | |
| 60 mM | 0.0371 mL | 0.1854 mL | 0.3707 mL | 0.9269 mL | |
| 80 mM | 0.0278 mL | 0.1390 mL | 0.2781 mL | 0.6951 mL | |
| 100 mM | 0.0222 mL | 0.1112 mL | 0.2224 mL | 0.5561 mL |
Valsartan methyl ester Related Classifications
HY-W414915 Related Classifications
Powered by Bioz